TRXB

10.3156.12%
CG

Carol G. Gallagher

Lead Independent Director

Dr. Carol G. Gallagher, PharmD, is Director of The Salk Institute For Biological STUDIES, San Diego, California. Dr. Gallagher served as a Chair of the Board at ChromaCode, Inc. She serves as Independent Director of PMV Pharmaceuticals, Inc. since November 4, 2022. She served as Independent Director at OncoResponse, Inc. from August 2023 to October 2025. She served as Independent Director at Mirati Therapeutics, Inc. since June 2023 until January 23, 2024. She was Director of Pionyr Immunotherapeutics Inc until March 2023. She serves as Director of Santa Maria Biotherapeutics, Inc. She served as Executive Chair of TRex Bio, Inc. from January 2025 to September 2026. Dr. Gallagher is an experienced Board Director having served as a Director in both public and private companies since 2011. Dr. Gallagher serves as an Independent Director at Frazier Lifesciences Acquisition Corporation. since October 2020. Dr. Gallagher serves as a Venture Advisor at New Enterprise Associates, Inc. She served as Venture Partner at New Enterprise Associates, Inc., since April 2020. She was a Partner of New Enterprise Associates, Inc., since joining it in October 9, 2014 until April 2020. She joined the firm in October 9, 2014. She had been an Independent Director of Certara, Inc. since June 2021 until April 05, 2022. She has been Trustee at Assabet Valley Bancorp. Dr. Gallagher had been Director of Turning Point Therapeutics, Inc. since July 25, 2019 until August 15, 2022. Dr. Gallagher is primarily focused on biopharma investments. She was a Venture Partner of Frazier Healthcare Ventures since joining it in October 2013 until September 2014. She had been an Independent Director at Metacrine, Inc. since November 2017 until April 1, 2021. She was a part of the life science team at Frazier Healthcare Ventures. She served as the President and Chief Executive Officer of Calistoga Pharmaceuticals Inc., since joining it in October 2008 until April 2011. She helped to build, advanced a first-in-class product through definitive, proof-of-concept studies in patients with certain lymphomas and leukemias. She served as the President and Chief Executive Officer of Metastatix since 2007 until 2008. During her career, Dr. Gallagher has led commercial, drug development and business development activities. She served as the President and Chief Executive Officer of Altiris Therapeutics Inc., since October 2007. She served as Chairman of the Board of Directors of Millendo Therapeutics since February 2013 until February 1, 2021 and serves as its Independent Director since 2012. She also serves as a Director at Recludix Pharma, Inc. She serves as an Independent Director of TRex Bio, Inc. since July 2019 and its Lead Independent Director since October 2026. She previously served as a Director at Seragon Pharmaceuticals. She served as a Rituxan Development Team Leader at Biogen Idec, where she led the Rituxan team when oncology sales first surpassed and the rheumatoid arthritis and multiple sclerosis development programs were designed. Dr. Gallagher served as Senior Vice President of Corporate Development & Commercial Affairs at Anadys Pharmaceuticals Inc., from June 4, 2007 to October 2007. She served as Vice President of Commercial Affairs at Anadys Pharmaceuticals Inc. from April 3, 2006 to June 4, 2007 and served as its Head of Corporate Development from April 2006 to October 2007 and Vice President of Corporate Development from April 2006 to June 4, 2007. She has an extensive leadership experience to the advancement. She was responsible for commercial affairs, including business development, market planning and strategic planning. She served as Vice President of Sales, Marketing and Product Planning of CancerVax Corp. from June 16, 2005 to March 2006. She provided commercial leadership for Canvaxin. She joined CancerVax in December 2003 as an Executive Director of Sales and Marketing. From January 2002 to November 2003, Dr. Gallagher served as Senior Director of Oncology Marketing at Biogen Idec, Inc. Prior to Biogen Idec, she served as Director of Global Marketing Planning at Oncology and Ophthalmology of Pfizer, Inc. She also served other marketing positions, including product and new product management roles at Agouron Pharmaceuticals, prior to the acquisition by Pfizer. From 1989 to 2007, she served various sales and marketing positions at both Eli Lilly and Co. Agouron Pharmaceuticals, Pfizer, Biogen Idec Pharmaceuticals, CancerVax, Anadys Pharmaceuticals. and Amgen Inc. She has extensive experience in drug development, commercialization and strategic leadership at large and small biopharmaceutical companies. She has a long and distinguished track record as an entrepreneur, executive and drug developer. She served as the Chairman for Atara Biotherapeutics, Inc until April 2020. She serves as a Director at Chromacode since December 2018 and Qpex BioPharma since August 2018. She had been an Independent Chairperson of Annexon Therapeutics, Inc. since June 23, 2016 until February 05, 2021 and served as its Director since September 2012. She served as Chairman of eFFECTOR Therapeutics Inc. She has been involved in M&A exits as well as IPOs. Dr. Gallagher serves as a Member of the Glaxo Smith Kline Discovery Investment Board. She serves as a Director of Pionyr Immunotherapeutics, Inc. since December 2017, Atterocor, Xoc Pharmaceuticals since October 2018 and served as a Director at Cleave Therapeutics, Inc. (formerly known as Cleave Biosciences, Inc.) since July 2016. She served as Director of Annexon, Inc since October 2018 until February 5, 2021. She serves as a Member of Corporate Advisory Board at Adaptive Biotechnologies Corporation. She was an Independent Director of Atara Biotherapeutics, Inc. since January 2013 until June 9, 2026 and served as its Lead Independent Director from December 2023 to September 2025 and served as its Chair of the Board since December 2022 until September 09, 2024. She served as an Executive Chairman of AnaptysBio Inc., from October 11, 2011 to September 9, 2015 and as its Director from November 2011 to March 5, 2018. She served as a Director of Altiris Therapeutics Inc. She served as an Independent Director of Aragon Pharmaceuticals Inc. since February 2012 until August 2013. She is a proven entrepreneur, operator and Investor with experience in commercial, drug development and business development roles. In 2019, she has been awarded Duane Roth Distinguished Contribution Award for Life Sciences Dr. Gallagher holds a Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky. She studied chemistry at Vanderbilt University.

Positions